Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components
about
Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritisCombination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT studyEvidence for early disease-modifying drugs in rheumatoid arthritisEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateModulation of Immune Responses by Exosomes Derived from Antigen-Presenting CellsEffect of combination therapy on joint destruction in rheumatoid arthritis: a network meta-analysis of randomized controlled trialsEfficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis.Cost-effectiveness of adding magnetic resonance imaging to rheumatoid arthritis management.EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsCombination treatment in autoimmune diseases. Methodology of combination trials.Combination therapy: the risks of infection and tumor induction.2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?Treatment strategy, disease activity, and outcome in four cohorts of patients with early rheumatoid arthritis.Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study.Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study.Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison.Comparing the long-term clinical outcome of treatment with methotrexate or sulfasalazine prescribed as the first disease-modifying antirheumatic drug in patients with inflammatory polyarthritisEULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).Radiological damage in patients with rheumatoid arthritis on sustained remission.Antimetabolites in the treatment of arthritis: current status of the use of antimetabolites.Leflunomide in rheumatoid arthritis: recommendations through a process of consensus.Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score.Safety and Efficacy of Methotrexate in Psoriasis: A Meta-Analysis of Published Trials.A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal.Methotrexate polyglutamates as a potential marker of adherence to long-term therapy in children with juvenile idiopathic arthritis and juvenile dermatomyositis: an observational, cross-sectional study.Aspects of early arthritis. Traditional DMARD therapy: is it sufficient?Treating very early rheumatoid arthritisCombination therapy for rheumatoid arthritis in the era of biologicalsTherapeutic options for rheumatoid arthritis.A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis.Current immunotherapy in rheumatoid arthritis.The optimal combination therapy for the treatment of early rheumatoid arthritis.Optimizing Methotrexate Treatment in Rheumatoid Arthritis: The Case for Subcutaneous Methotrexate Prior to Biologics.Neutropenia in the Elderly: A Rheumatology Perspective.Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis.Reductions in radiographic progression in early RA over 25-years: Changing contribution from RF in 2 multi-centre UK inception cohorts.Treatment comparison in rheumatoid arthritis: head-to-head trials and innovative study designsTreatment of rheumatoid arthritis with methotrexate alone and in combination with other conventional DMARDs using the T2T strategy. A cohort study.How should impaired morning function in rheumatoid arthritis be treated?
P2860
Q24235784-7B6D6912-D807-4AB9-9534-481B468E7AE2Q24674942-C26EA884-C3ED-4CC1-855C-B5CD491341D3Q24793240-DEDE1417-C62C-4264-B070-4B5ED7B458AEQ26859134-1779502E-865E-484C-B4FD-091799A888C8Q28066545-98C87C49-59B7-41CE-9F66-C95362AEEB67Q28543128-CC93AEFC-A755-4C5E-8605-6F5764C665A6Q33389401-C2D9C08D-1D64-4021-A3B1-5203B46136B5Q33717053-9916B9A3-7793-4E93-8D66-55517F581CE4Q34110066-D8143629-ED72-4121-AB59-5EE21921FF6EQ34309734-40E15799-582B-4A5A-8818-509377A292F9Q34309757-D026CA2F-C473-4CD0-A914-3709218F4446Q34500921-9EE431A7-B99E-4367-A5B9-80BA72304117Q34559803-AD6E49E4-F5BB-4F07-A768-D9B5A5E2AA1DQ35550470-1A9E94E6-F232-4541-940B-2475CFCD1CB6Q35554180-54E09CE9-9DAB-4A86-A226-E635549E46DDQ35555878-4B1BB5FC-D848-4433-BE08-D24285013C2EQ35637985-2AB98406-D99F-4B3E-8EDE-A82A4D6F8EACQ35638194-4665B1FD-DECC-44F2-AA62-77BAEEACF7E1Q35638360-CD3058C9-4EC8-4C70-A69B-C9E823696D16Q35759974-1DF1A1C6-FDD7-43B2-A066-1197ADA1286EQ35967177-11A8C06D-58D1-42E4-AC6C-1AE1779BEF50Q36013041-CA27B926-4948-4262-98F7-27365C84E321Q36013828-F5C873A7-1DDA-41DB-8AEB-0D2C68880DE1Q36014642-95267916-A791-4D71-97B5-F58466426899Q36200678-50474FB1-B99E-4129-A7C1-E67E491F8664Q36202845-E6D7249E-1296-4AFB-BD96-32BBAFD2A5D2Q36486374-DC6D1AD5-A11F-4116-991B-833FE62AA423Q36596130-E6B204AA-5AAF-4F3F-9F33-2D350E92DD31Q36823684-B222D412-383C-431E-B0C4-92748205C65CQ37552947-F7473FCB-08C1-4AF6-BD7E-677DD1707C52Q37633796-8DC1259D-A61F-49E7-9BC0-11CA030E0172Q38133655-51C00CE2-0B30-4613-9685-8509FEB5C213Q38522457-73F40B90-8C08-41B7-AC41-8A915EDF504DQ38609272-686288E8-E6C8-4A21-AB8E-2C5199BC914AQ38893238-A85C09E0-F906-4275-B5CE-D0EB571D16F9Q38939820-E04DA713-863B-4CC5-B990-49BAC4AC78B0Q38952206-4A864247-F6E7-41B6-9572-A90D48A64970Q41450339-E95DFAAC-4A5C-4E6B-A64F-172CACE93378Q41919866-94DEC490-877F-4ACA-A151-524910B9ACA0Q44083454-DC5F93F3-299C-46CF-A61E-DF38D9CC336A
P2860
Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components
description
1999 nî lūn-bûn
@nan
1999 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Combination therapy in early r ...... red with the single components
@ast
Combination therapy in early r ...... red with the single components
@en
Combination therapy in early r ...... red with the single components
@nl
type
label
Combination therapy in early r ...... red with the single components
@ast
Combination therapy in early r ...... red with the single components
@en
Combination therapy in early r ...... red with the single components
@nl
prefLabel
Combination therapy in early r ...... red with the single components
@ast
Combination therapy in early r ...... red with the single components
@en
Combination therapy in early r ...... red with the single components
@nl
P2093
P2860
P3181
P356
P1476
Combination therapy in early r ...... red with the single components
@en
P2093
A Cantagrel
M Dougados
M Leirisalo-Repo
M Schattenkirchner
P Goupille
P2860
P3181
P356
10.1136/ARD.58.4.220
P407
P577
1999-04-01T00:00:00Z